This study is designed to determine the safety and efficacy of non-operative antibiotic management of clinically diagnosed acute uncomplicated appendicitis in children. Enrolled patients will be randomised and an allocation ratio of 1:1 will be made via weighted minimisation, where half of the patients will receive non-operative management with intravenous Piperacillin with Tazobactam, while the other half will have an appendicectomy.
Appendicectomy for acute appendicitis is one of the most commonly performed paediatric emergency operations in Australia. This standard treatment of acute uncomplicated appendicitis (AUA) has remained largely unchallenged since its introduction in the late nineteenth century, under the assumption that AUA progresses to perforation and thus complications should an operation be withheld. However, appendicectomy via laparoscopic or open approach is not without its risks. Non-operative management (NOM) with antibiotics has been increasingly accepted as mainstay therapy for many intra-abdominal infections. In fact, children with appendicitis complicated by perforation, abscess or phlegmon formation are often preferentially treated non-operatively with antibiotic therapy, with or without percutaneous drainage. Systematic reviews and meta-analyses have demonstrated that antibiotics are a safe and effective treatment for AUA in adults and there is growing evidence that NOM is safe and effective in children. Primary objectives: To determine the safety and efficacy of non-operative antibiotic management of clinically diagnosed likely AUA in children. Secondary objectives: 1. To compare the safety and efficacy of NOM of clinically diagnosed likely AUA with operative management (OM) in children. 2. To assess the cost-effectiveness of NOM of clinically diagnosed likely AUA against OM in children. 3. To assess the feasibility and acceptability of NOM of appendicitis in children. This study will enrol 226 patients, age 5-16 years, with acute uncomplicated appendicitis at two tertiary children's hospitals. Allocation ratio of 1:1 will be made via weighted minimisation using the following criteria: age (5-8 years or 9-16 years), gender (male or female), and duration of symptoms (\<48 or \>48 hours).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
226
With intravenous Piperacillin with Tazobactam (Tazocin)
Sydney Children's Hospital
Randwick, New South Wales, Australia
RECRUITINGThe Children's Hospital at Westmead
Westmead, New South Wales, Australia
NOT_YET_RECRUITINGUnplanned or unnecessary operation(s) and complications
Time frame: 30 days
Unplanned or unnecessary operation, or complications
Time frame: 6 months
Length of primary hospital stay
Time of randomisation to discharge
Time frame: 72 hours
Treatment-related complications
Time frame: 12 months
Redamission and Emergency Department presentation
Time frame: 12 months
Cost of treatment in Australian Dollars (AUD)
Time frame: 12 months
Return to school from time of randomisation
Time frame: 30 days
Return to normal activities from time of randomisation
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.